89813-47-8

Basic information

• Product Name: BOC-HYP-OBZL
• Synonyms: (2S,4R)-4-Hydroxy-1,2-Pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) 2-(phenylmethyl) ester;N-(tert-Butoxycarbonyl)-4-hydroxyproline benzyl ester;N-Boc-trans-4-hydroxy-L-proline benzyl ester, 95%;Boc-trans-L-4-hydroxyproline benzyl ester;Benzyl (4R)-1-Boc-4-hydroxy-L-prolinate;2-Benzyl 1-(tert-butyl) (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate;Boc-L-Hyp-OBzl;Boc-trans-L-4-hydroxyproline benzyl ester≥ 95% (HPLC)
• CAS NO: 89813-47-8
• Molecular Formula: C₁₇H₂₃NO₅
• Molecular Weight: 321.37
• Mol File: 89813-47-8.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 441.4±45.0 °C(Predicted)
• Appearance: Pale brown/Liquid
• Density: 1.225
• Storage Temp.: 2-8°C
• PKA: 14.26±0.40(Predicted)
• CAS DataBase Reference: BOC-HYP-OBZL(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-HYP-OBZL(89813-47-8)
• EPA Substance Registry System: BOC-HYP-OBZL(89813-47-8)

Safety Data

• Hazardous Substances Data: 89813-47-8(Hazardous Substances Data)

Usage

Chemical Properties

Yellowish oil

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 100-44-7 benzyl chloride 
• 51-35-4 4R-4-hydroxyproline 
• 1738-76-7 glycine benzyl ester p-toluenesulfonic acid salt 
• 1332341-02-2 benzyl (2S)-2-Boc-amino-3-(2-oxiranyl)propionate 
• 871979-68-9 3-[2-((4R)-acetoxy-1-tert-butoxycarbonyl-(2S)-pyrrolidinyl)-5-thiazolyl]propionic acid methyl ester 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 88501-00-2 (2S,4R)-4-hydroxyproline benzyl ester p-toluenesulfonate 

Downstream Products

• 185304-16-9 (2S,4S)-4-(Toluene-4-sulfonyloxy)-pyrrolidine-1,2-dicarboxylic acid 2-benzyl ester 1-tert-butyl ester 
• 288582-37-6 N-[(2S,4S)-4-[2-(benzyloxycarbonyl)-1-(tert-butyloxycarbonyl)pyrrolidinyl]]-D-serine benzyl ester 
• 874162-95-5 (2S,4S)-1-(tert-butoxycarbonyl)-4-bromoproline benzyl ester 
• 221352-74-5 (2S,4S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-(tert-butoxycarbonylamino)pyrrolidine2-carboxylic acid 
• 62147-27-7 (2S,4R)-benzyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride 
• 871980-67-5 3-[2-[1-[5-chloro-2-fluoro-4-(1-methyl-3-indolylcarbonylamino)phenylacetyl]-(4S)-[1-(4-(2,2,2-trifluoro)ethyl)piperazinyl]-(2S)-pyrrolidinyl]-5-thiazolyl]propionic acid methyl ester 
• 865469-50-7 N-(tert-Butoxycarbonyl)-(2S,3R,4S)-3,4-dihydroxyproline benzyl ester 

Relevant articles and documents

PI3K INHIBITORS AND USES THEREOF

The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3Kα inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3Kα) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.

A short diastereoselective synthesis of cis-(2S,4S) and cis-(2R,4R)-4-hydroxyprolines

A concise synthesis of (2R,4R)-4-hydroxyproline (1) and (2S,4S)-4-hydroxyproline (2) has been developed in enantiomerically pure form from commercially available starting materials with excellent diastereoselectivity. The tightly bound chelation controlled transition state formed during the 5-exo-tet ring closure reaction is assumed to be the origin of high diastereoselectivity.

SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and their use in methods of treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.